

## Summary

This summary of 510(k)-safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR § 807.92.

### 1. Company making the submission:

**JUL 30 2009**

Name: Gish BioMedical, Inc.  
A member of the MEDOS group  
Address: 22942 Arroyo Vista  
Rancho Santa Margarita, CA 92688-  
2600  
Telephone: 949-635-6200 voice  
949-635-6294 fax  
janetp@gishbiomedical.com  
Contact: Janet Peets  
Regulatory & Clinical Affairs  
Specialist

### 2. Device:

Proprietary Name: Medos Hilite MVC 4030 Hardshell Venous Reservoir  
Common Name: Cardiopulmonary Blood Reservoir  
Classification Name: Extracorporeal Circuit Blood Defoamer  
Cardiopulmonary Bypass Blood Reservoir

### 3. Predicate Devices:

Gish CAPVRF45 Hardshell Venous Reservoir, K964973, manufactured by Gish Biomedical, Inc.

### 4. Classifications Names & Citations:

21 CFR 870.4230, 21 CFR 870.4400, Extracorporeal circuit blood defoamers, Cardiopulmonary bypass blood reservoir, Cardiopulmonary Bypass, Class II, DTN, Cardiovascular.

### 5. Description:

The MEDOS HILITE MVC 4030 Hardshell Venous Reservoirs are sterile, non-pyrogenic, single use, disposable, device designed for collection, storage and filtration of blood during cardiopulmonary bypass. The MEDOS HILITE MVC 4030 has a clear polycarbonate shell and an internal defoamer filter cartridge. Venous drainage enters the 1/2" venous inlet at the center top section of the lid. Venous suctioned blood enters the top section of the defoamer/filter cartridge and passed through a defoamer sponge and 30 micron filter. The maximum venous flow rate is 7 lpm. The maximum cardiectomy flow rate is 4 lpm.

---

**6. Indications for use:**

The MEDOS HILITE MVC 4030 Hardshell Venous Reservoir is indicated for use during cardiopulmonary bypass surgery as a storage reservoir for gravity and augmented venous return blood and to filter and defoam intrathoracic suctioned blood prior to its return to the extracorporeal circuit at flow rates of one (1.0) to seven (7.0) liters per minute for periods up to six hours (6.0) hours.

**7. Contra-indications:**

No contra-indications have been noted.

**8. Comparison:**

The Medos Hilite MVC 4030 Hardshell Venous Reservoir has the same device characteristics as the predicate devices.

**9. Test Data:**

The MEDOS HILITE MVC 4030 Hardshell Venous Reservoir has been subjected to extensive safety, performance, and validations prior to release. Final testing for the system includes various performance tests designed to ensure that the device meets all of its functional requirements and performance specifications. Safety tests have further been performed to ensure the device complies with applicable industry and safety standards.

**10. Literature Review:**

A review of literature pertaining to the safety and effectiveness has been conducted. Appropriate safeguards have been incorporated in the design of MEDOS HILITE MVC 4030 Hardshell Venous Reservoir.

**11. Conclusions:**

Based upon the testing and comparison to the predicate device the Medos Hilite MVC 4030 Hardshell Venous Reservoir has the same intended use, with similar technological characteristics. Gish Biomedical, Inc., therefore posits that its device is equivalent in safety and effectiveness to predicate devices.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

JUL 30 2009

Gish Biomedical, Inc.  
c/o Ms. Janet Peets  
22942 Arroyo Vista  
Rancho Santa Margarita, CA 92688

Re: K083131  
Medos Hilite MVC 4030 Reservoir  
Regulation Number: 21 CFR 870.4400  
Regulation Name: Reservoir, blood, cardiopulmonary bypass  
Regulatory Class: Class II (two)  
Product Code: DTN  
Dated: June 10, 2009  
Received: June 11, 2009

Dear Ms. Peets:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Page 2 – Ms. Janet Peets

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Bram D. Zuckerman, M.D.  
Director  
Division of Cardiovascular Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

510(k) Number K 083131

Device Name: MEDOS HILITE MVC 4030 Hardshell Venous Reservoir

**Indications for use:**

The MEDOS HILITE MVC 4030 Hardshell Venous Reservoir is indicated for use during cardiopulmonary bypass surgery as a storage reservoir for gravity and augmented venous return blood and to filter and defoam intrathoracic suctioned blood prior to its return to the extracorporeal circuit at flow rates of one (1.0) to seven (7.0) liters per minute for periods up to six hours (6.0) hours.


**Prescription Device:**

Federal Law (US) restricts this device to sale by or on the order of a physician.

Prescription Use : Yes OR Over-The-Counter Use: No

PLEASE DO NOT WRITE BELOW THIS LINE- CONTINUE ON ANOTHER PAGE IF  
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
\_\_\_\_\_  
(Division Sign Off)  
Division of Cardiovascular Devices  
510(k) Number K083131